Basics Syros Pharmaceuticals, Inc. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY-1425 and SY-1365. IPO Date: June 30, 2016 Sector: Healthcare Industry: Biotech Activated in VL: True Average Daily Range Avg Daily Range: $0.27 | 3.91% Avg Daily Range (30 D): $0.01 | 18.06% Avg Daily Range (90 D): $0.01 | 11.66% Institutional Daily Volume Avg Daily Volume: 1.03M Avg Daily Volume (30 D): .15M Avg Daily Volume (90 D): 13.36M Trade Size Avg Trade Size (Sh.): 388 Avg Trade Size (Sh.) (30 D): 1,929 Avg Trade Size (Sh.) (90 D): 1,579 Institutional Trades Total Inst.Trades: 229 Avg Inst. Trade: $1.67M Avg Inst. Trade (30 D): $2M Avg Inst. Trade (90 D): $2M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.85M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 24.52K         News May 12, 2025 @ 5:00 PM Blood Cancer Treatment Market Sees Accelerated Gro... Source: Delveinsight Jul 3, 2024 @ 3:35 AM Syros pharmaceuticals director sells $178k in comp... Source: Investing.Com May 8, 2024 @ 12:15 PM 2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Re... Source: Zacks Equity Research May 2, 2024 @ 2:01 PM Will Femasys Inc. (FEMY) Report Negative Q1 Earnin... Source: Zacks Equity Research May 1, 2024 @ 2:01 PM Analysts Estimate Syros Pharmaceuticals, Inc. (SYR... Source: Zacks Equity Research Financials   TTM Q3 2024 Q2 2024 Basic EPS $-3.07 $-.16 $-.59 Diluted EPS $-3.07 $-.16 $-.59 Revenue $ .39M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -97.82M $ -6.4M $ -23.33M Operating Income / Loss $ -111.66M $ -26.18M $ -27.42M Cost of Revenue $ $ $ Net Cash Flow $ -54.91M $ -20.69M $ -4.56M PE Ratio     Splits Sep 19, 2022:   1:10